Education
About Us
Working with TipRanks
Follow Us
AbSci (ABSI)
NASDAQ:ABSI
ABSI Stock Chart & Stats
Day’s Range― - ―
52-Week Range$2.45 - $6.72
Previous CloseN/A
Volume51.94M
Average Volume (3M)4.83M
Market Cap
$383.28M
Enterprise Value$303.13M
Total Cash (Recent Filing)-$13.09M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta2.90
Next Earnings
May 20, 2025EPS Estimate
-0.22Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.93
Shares Outstanding127,333,885
10 Day Avg. Volume4,077,024
30 Day Avg. Volume4,832,368
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)84.53
Price to Cash Flow (P/CF)-5.70
P/FCF Ratio0.00
Enterprise Value/Market Cap0.79
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-7.24
Enterprise Value/Ebitda-3.64
Forecast
1Y Price Target
$8.33Price Target Upside168.71% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering8
---
AbSci News
---
Bulls Say, Bears Say
Bulls Say
Financial PositionAbsci had approximately $112M in cash and cash equivalents at the end of 4Q24 and raised approximately $40M in equity funding since then, resulting in a pro forma cash balance of $152M.
Partnerships And CollaborationsAbsci's breakthrough in developing HIV antibodies and Advanced Micro Devices' recent $20M equity investment strongly validate Absci's AI capabilities.
Product DevelopmentABS-101 showed the strongest odds of demonstrating a best-in-class clinical profile in the race to develop anti-TL1As for inflammatory bowel disease.
Bears Say
Financial PerformanceFor 4Q24, the company reported revenues of $0.7M, which was below the consensus estimate of $1.8M, and a net loss of $0.25 per share, compared to the consensus estimated net loss of $0.22 per share.
Revenue ExpectationsQ4 revenues of $0.7M brought FY24 total revenues to $4.5M, below expectations.
---
Ownership Overview
27.79% Insiders
20.23% Mutual Funds
27.57% Other Institutional Investors
7.30% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
ABSI FAQ
What was AbSci’s price range in the past 12 months?
AbSci lowest stock price was $2.45 and its highest was $6.72 in the past 12 months.
What is AbSci’s market cap?
AbSci’s market cap is $383.28M.
When is AbSci’s upcoming earnings report date?
AbSci’s upcoming earnings report date is May 20, 2025 which is in 55 days.
How were AbSci’s earnings last quarter?
AbSci released its earnings results on Mar 18, 2025. The company reported -$0.25 earnings per share for the quarter, missing the consensus estimate of -$0.224 by -$0.026.
Is AbSci overvalued?
According to Wall Street analysts AbSci’s price is currently Undervalued.
Does AbSci pay dividends?
AbSci does not currently pay dividends.
What is AbSci’s EPS estimate?
AbSci’s EPS estimate is -0.22.
How many shares outstanding does AbSci have?
AbSci has 127,333,885 shares outstanding.
What happened to AbSci’s price movement after its last earnings report?
AbSci reported an EPS of -$0.25 in its last earnings report, missing expectations of -$0.224. Following the earnings report the stock price went down -3.247%.
Which hedge fund is a major shareholder of AbSci?
Currently, no hedge funds are holding shares in ABSI
---
AbSci Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$8.33 (168.71% Upside)
$8.33 (168.71% Upside)
Blogger Sentiment
Bullish
ABSI Sentiment 100%
Sector Average 69%
Sector Average 69%
Crowd Wisdom
Very Negative
Last 7 Days <0.1%
Last 30 Days ▼ 7.6%
Last 30 Days ▼ 7.6%
News Sentiment
Very Bearish
Bullish news 0%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-42.99%
12-Months-Change
Fundamentals
Return on Equity
-58.04%
Trailing 12-Months
Asset Growth
-8.90%
Trailing 12-Months
Company Description
AbSci
AbSci Corporation (ABSI) operates in the biotechnology sector, focusing on transforming the process of drug discovery and development. The company utilizes its proprietary synthetic biology platform to enable the creation and production of complex biological molecules, including antibodies and other therapeutic proteins. AbSci's platform aims to accelerate the development of new drugs and optimize protein production processes for biopharmaceutical companies.
---
ABSI Earnings Call
Q4 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call highlighted Absci's achievements in advancing their AI drug creation platform and securing strategic partnerships, which contribute to their long-term potential. However, increased R&D expenses and decreased quarterly revenue suggest some immediate financial challenges. The sentiment is balanced given the strong future outlook offset by current financial metrics.Read More>---
ABSI Stock 12 Month Forecast
Average Price Target
$8.33
▲(168.71% Upside)
Technical Analysis
Editas Medicine
―
Intellia Therapeutics
―
Crispr Therapeutics AG
―
Twist Bioscience
―
Ginkgo Bioworks Holdings
―
Best Analysts Covering ABSI
1 Year
1 Year Success Rate
6/12 ratings generated profit
1 Year Average Return
+48.96%
reiterated a buy rating 8 days ago
Copying Swayampakula Ramakanth's trades and holding each position for 1 Year would result in 50.00% of your transactions generating a profit, with an average return of +48.96% per trade.
---